Design, synthesis and pharmacological evaluation of novel 2-chloro-3-(1H-benzo [d]imidazol-2-yl) quinoline derivatives as antitumor agents: in vitro and in vivo antitumor activity, cell cycle arrest and apoptotic response † generation, p21, p27 and p53, downregulation of Bcl-2, activation of caspase-9 and caspase-3 and subsequent cleavage of PARP, and inhibition of CDK activity.
Introduction
As one of the second leading causes of mortality, cancer is a great concern to mankind. Due to negative lifestyle and food habits, which seriously increase the cancer risk, more and more people around the globe are diagnosed with this disease.
1,2
Therefore, the discovery and development of promising new antitumor agents with high efficiency and low toxicity to healthy cells and tissues have become urgent and key focuses of pharmaceutical chemists worldwide. To realize this goal, a great deal of attention is being focused on molecules that act synchronously on multiple targets by combining two/more active pharmacophores covalently in a single-hybrid molecule with dual/multiple antitumor effects. 3, 4 This combination principle strategy encouraged us to design, synthesize and evaluate a new set of hybrid molecules by combining two pharmacophores present in a number of natural and synthetic agents: chloroquinoline and benzimidazole.
Quinoline and its derivatives display a variety of powerful biological activities including inhibition of cellular proliferation and developmental changes, [5] [6] [7] which make the quinoline ring a valuable versatile synthetic scaffold for new antitumor agents. Among the various existing active scaffolds of quinolines, chloroquinoline is a type of alkaloid, which is as abundant as quinoline. Previous studies have indicated that chloroquinoline derivatives display preferable biological activities such as anticancer and antiproliferation activities.
8,9
Chloroquinoline scaffold is thus chosen in the present study as an active antitumor pharmacy core, and some structural modications are designed to explore the antitumor activity. In addition, a bicyclic compound, namely, benzimidazole, which is the fusion of benzene and imidazole, is a pharmacophore possessing a wide range of biological activities.
10 Some benzimidazole derivatives have been found to display potent antitumor activities. [11] [12] [13] Accordingly, the benzimidazole nucleus has been considered as an important pharmacophore in antitumor chemistry. It is thus expected that combining the chloroquinolone scaffold with the benzimidazole skeleton may lead to potent antitumor activity. Therefore, under the combination principle, a set of 2-chloroquinoline-benzimidazole derivatives 3(3a 1 À3d 6 ) were synthesized, and their antitumor activities were evaluated. Moreover, previous studies have indicated that both quinoline and benzimidazole derivatives exert antitumor activities through modulation of cell cycle arrest and apoptotic responses. [14] [15] [16] Therefore, mechanistic studies focused on apoptosis and cycle arrest induced by the representative compound 3a 1 were also performed.
Results and discussion

Chemistry
2-Chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives 3(3a 1 À3d 6 ) were synthesized as shown in Scheme 1. First, 2-chloro-quinoline-3-carbaldehyde derivatives 2(2aÀ2d) were synthesized through the Vilsmeier-Haack-Arnold reaction, which involves the combination of acetanilide derivatives 1(1aÀ1d) with N,N-dimethylformamide (DMF) in the presence of phosphorus oxychloride.
15
2-Chloro-quinoline-3-benzimidazole derivatives 3(3a 1 À3d 6 ) were then obtained in moderate yields by the condensation reactions of 2(2aÀ2d) with o-phenylenediamine derivatives in the presence of methanol. The structures of compounds 3(3a 1 À3d 6 ) were conrmed using various spectroscopic methods including 1 H NMR, 13 C NMR and the structures shown in Scheme 1, thus indicating that the structures of compounds 3(3a 1 À3d 6 ) were conrmed.
In vitro antiproliferative activity
The in vitro antiproliferative activities of the compounds 3(3a 1 À3d 6 ) were evaluated against HepG2 (human liver cancer cells), SK-OV-3 (human ovarian cancer cells), NCI-H460 (human large cell lung cancer cells), BEL-7404 (human liver cancer cells) and HL-7702 (human liver normal cells) cell lines, using the methylthiazol tetrazolium (MTT) assay. 15, 17 Two commercial anticancer drugs 5-uorouracil (5-FU) and cisplatin were used as positive controls. The results are shown in Table 1 . Table 1 indicates that many compounds showed evident antiproliferative activities against HepG2, SKOV3, NCI-H460 and BEL-7404 cell lines, and some displayed better antiproliferative activities than 5-FU and cisplatin while exhibiting lower cytotoxicities against the HL-7702 normal cell line. In the HepG2 cell line assay, compounds 3a 1 , 3a 3 , 3a 4 , 3a 5 , 3c 3 , 3c 4 , 3c 5 Table 1 , it can be concluded that for compounds 3(3a 1 À3d 6 ), the absence of substitution and the methoxy substitution at 6 position of quinolone moiety as well as dimethyl, chloro and bromo substitutions in the benzimidazole moiety had positive effects on the antiproliferative activity.
Among the compounds 3(3a 1 À3d 6 ), the compound 3a 1 showed the best potential antiproliferative activity against these cancer cell lines. Thus, 3a 1 was selected as a representative compound for in vivo antiproliferative activity and mechanistic studies.
Preliminary safety evaluation of 3a 1
The in vivo toxicity of compound 3a 1 was evaluated in Kun-ming (KM) mice. Through intraperitoneal injection, the mice received 3a 1 (dissolved in 5% v/v DMSO/saline solvent) at a dose of 50 mg kg À1 per day for 8 consecutive days; then, for the next 6 days, the mice were treated with compound 3a 1 at the same dose once every two days. The body weights of the animals were monitored daily and used as a parameter of systemic toxicity.
No adverse effects were observed in the KM mice injected with 3a 1 during the 14 day monitoring period. As shown in Fig. 1 , the average body weights of the mice treated with 3a 1 showed similar growth rates to those of the control group. It is also worth noting that, as shown in Fig. 1 , the injection of 3a 1 even led to extra weight gain in the KM mice, indicating that no adverse effects were found aer the treatment of these mice with 3a 1 .
2.4.
In vivo antiproliferative activity of 3a 1 The potential in vitro antiproliferative activity and the absence of adverse effect of 3a 1 encouraged us to perform in vivo antiproliferative assays to further evaluate its antitumor activity. The HepG2 xenogra model was selected in this study, and paclitaxel was used as the positive control. SPF BALB/c nude mice were randomly divided into vehicle control group, low dose of 3a 1 -treated group, high dose of 3a 1 -treated group, and positive control group. The mice in the vehicle control group were injected with 5% DMSO saline solution, and the mice in low and high dose of 3a 1 -treated group were injected with 3a 1 (in 5% DMSO saline solution), whereas the mice in the positive control group were injected with paclitaxel (in 5% DMSO saline solution). Tumor size of mice was tested twice in a week in two dimensions, and the volume was measured to evaluate in vivo antitumor activity.
As shown in Fig. 2 , compared with the observations for control, the treatment with 3a 1 and paclitaxel signicantly inhibited the increase in the tumour volume in mice, indicating that compound 3a 1 exhibited potential antitumor effect. The treatment of high dose of 3a 1 (20 mg kg In addition, no evident changes in the body weight and no other adverse effects were found in the mice treated with 3a 1 (at 20 mg kg À1 dose) (Fig. S1-1 †), suggesting that 3a 1 may be a good candidate for an antitumor agent. >100 >100 >100 >100 >100 3b1(3d) >100 >100 >100 >100 >100 3b2(3n) >100 >100 >100 >100 >100 3b3(3r) >100 >100 >100 >100 >100 3b4(3j) >100 >100 >100 >100 >100 3b5(3f) >100 >100 >100 >100 >100 3b6(3v) >100 >100 >100 >100 >100 3c1(3a)
37.81 AE IC 50 values are presented as mean AE SD (standard error of the mean) from three repeated experiments. Fig. 1 Changes in the body weight of KM mice injected with compound 3a 1 . There are six mice in each experimental group.
Study on cell cycle distribution
As signicant control mechanisms, cell cycle checkpoints control and ensure the generation and performance of cell cycle events. 18 To study the potential role of cell cycle arrest in tumor cell death induced by compounds 3, HepG2 cells were treated with the representative compound 3a 1 at different concentrations (0, 6, 8 and 10 mM) for 48 h. As shown in Fig. 3 , the treatment of HepG2 cells with 3a 1 promoted cell cycle arrest at the G 2 phase, which led to a clear increase in the G 2 -phase population (34.80% at 6 mM, 40.65% at 8 mM and 53.33% at 10 mM) compared with the observations in the control group (19.04%). Consequently, the G 1 -phase and S-phase populations of the HepG2 cells decreased. The results indicated that compound 3a 1 clearly arrested the cell cycle of HepG2 cells at the G 2 /M stage in a concentration-dependent manner. Effects of compounds 3a 1 on the expression levels of relevant proteins in HepG2 cells. western blot analysis was performed with antibodies against cyclin B1, CDK1, CDC25C, p21, p23, and p53. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading standard.
Cyclin B1/CDK1(CDC2) kinase complexes are main regulators of G 2 /M transition, and their generation is usually monitored by the positive mediator cell division cyclin 25 homolog C (CDC25C) phosphatase.
19,20 CDC25C mediates the phosphorylation of CDK1 and consequently leads to the activation of cyclin B1/CDK1 complexes and execution of G 2 /M transition;
19,20 phosphorylation of CDC25C accompanied by DNA damage and cellular activities resulting in G 2 /M arrest causes its degradation and sequestration to the cytoplasm, which consequently leads to the destabilization of the cyclin-CDK complexes. 21 The p53, p27 and p21 genes encoded by some antioncogenes are also involved in the G 2 /M arrest through increasing the accumulation of the dormant cyclin B-CDK complex. 22 Therefore, in the present study, the expression levels of cyclin B1, CDK1, CDC25C, p53, p27 and p21 in the HepG2 cells were assayed using western blot. As shown in Fig. 4 , compared to the observations for the control, the lysates of the HepG2 cells treated with 3a 1 down-regulated the levels of cyclin B1, CDK1 and CDC25C while up-regulating the levels of p53, p21 and p27. Thus, compound 3a 1 induced G 2 /M phase cell cycle arrest through inhibition of CDK activity and increase in the expression levels of p53, p27 and p21.
Apoptosis assays
Apoptosis is another important mechanism in cancer treatment, and it is a key pathway leading to cell death. 23, 24 Thus, the apoptosis-inducing effect of compound 3a 1 was investigated by staining with the uorescent probes Hoechst 33 258 and acridine orange/ethidium bromide (AO/EB). In the Hoechst 33 258 staining assay (Fig. 5) , normal HeGp2 cells emitted blue uo-rescence, whereas the cells treated with 3a 1 for 12 h exhibited stronger blue uorescence and displayed characteristic apoptotic morphologies. This phenomenon indicated that compound 3a 1 induced the apoptosis of HeGp2 cells. 21 In the AO/EB staining assay, the morphology of 3a 1 -treated HeGp2 cells exhibited evident changes (Fig. 6) . The cell nuclei were stained yellow/orange, and the morphology changes suggested pycnosis, membrane blebbing and cell budding, all of which are clear characteristics of apoptosis.
21 Therefore, on the basis of the above-mentioned observations, it can be concluded that the compound 3a 1 induced apoptosis of HeGp2 cells.
The apoptosis ratios of HepG2 cells treated with 3a 1 were then quantitatively assayed by ow cytometry. As shown in Fig. 7 , the treatment of HepG2 cells with compound 3a 1 at different concentrations (6, 8 and 10 mM) led to signicant increase in the apoptotic cell population in a concentrationdependent manner. The results indicated that compound 3a 1 induced apoptosis of HepG2 cells in a dose-dependent manner.
ROS generation
A previous study proved that the generation of intracellular reactive oxygen species (ROS) can induce apoptosis. 25 To investigate the role of ROS in 3a 1 -induced apoptosis in the HepG2 cells, intracellular ROS levels were determined through uorescence microscopy using 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI) and 2,7-dichlorouorescein diacetate (DCFH-DA) as uorescent probes. Fig. 8 demonstrates that both control cells and HepG2 cells treated with compound 3a 1 displayed blue uorescence in the cytoplasm in the DAPI staining assay, whereas the HepG2 cells treated with compound 3a 1 exhibited stronger green uorescence signals compared to the control in the DCFH-DA staining assay, indicating that 3a 1 can up-regulate the levels of intracellular ROS. These results indicated that the generation of ROS induced by 3a 1 may be an underlying cause for apoptosis. 24 
Intracellular Ca 2+ release
It is known that intracellular calcium takes part in cell apoptosis, and an overload of calcium can induce apoptosis.
26
Thus, the role of calcium signaling in cellular apoptosis induced by 3a 1 was studied. The HepG2 cells were treated with 3a 1 for 24 h, and the intracellular Ca 2+ level was assayed by uorescence microscopy using DCFH-DA as a calcium probe. Fig. 9 shows that the treatment of HepG2 cells with 3a 1 caused an increase in the intracellular Ca 2+ concentration, indicating that 3a 1 -induced apoptosis was related to the up-regulation of intracellular Ca 2+ level.
Caspase-dependent apoptosis in HepG2 cells
As well-known anti-and pro-apoptotic proteins, Bcl-2/Bax family proteins play important roles in the inhibition or promotion of cell death. 27,28 A previous study proved that the ratio of Bcl-2/Bax expression is vital in the regulation of apoptosis.
29 Bcl-2/Bax family proteins mainly participate in apoptosis by interfering with caspases, which are the pivotal effectors of programmed cell death. 30, 31 Caspases are a family of cysteinyl aspartate specic proteases, which participate in apoptosis, and they can be divided into initiators (caspases 8, 9 and 10) and executioners (caspases 3, 6 and 7). 30, 31 The caspase cascade is mediated by the proteolysis of inactive procaspases and propagated by the cleavage of downstream caspases and substrates including poly(ADP-ribose) polymerase (PARP). 21 To investigate the mechanism of 3a 1 -induced apoptosis in cancer cells and to nd if caspases were involved in 3a 1 -induced apoptosis, the expression levels of Bax, Bcl-2, cytochrome c, caspase-9, caspase-3 and PARP in HepG2 cells treated with 3a 1 were assayed by western blot. As shown in Fig. 10 , the treatment of HepG2 cells with 3a 1 led to evident increase in the expression levels of Bax, caspase-9, caspase-3 and PARP and reduction in the expression level of Bcl-2 accompanied by the release of mitochondrial cytochrome c into the cytosol compared to the observations for control. These results indicated that compound 3a 1 could down-regulate the expression of Bcl-2, leading to the release of cytochrome c, activation of caspase-9 and induction of apoptosis, thus demonstrating that compound 3a 1 exerted pro-apoptotic effects through a mitochondrial-mediated pathway and caspase cascade.
Conclusions
In summary, we designed and synthesized a set of 2-chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives and evaluated the antiproliferative activities of these compounds against four cancer cell lines (HepG2, SKOV-3, NCI-H460 and BEL-7404). We identied some compounds exhibiting high in vitro anticancer activities and low toxicities against normal HL-7702 cells. In vivo antitumor activity study and animal toxicology test showed that 3a 1 exhibited potent antitumor activity in the HepG2 xenogra mouse model. Mechanistic studies showed that 3a 1 caused apoptosis of tumor cells possibly through regulation of the expression levels of apoptotic proteins (such as Bax, Bcl-2, cytochrome c, caspase-9, caspase-3, and PARP), intracellular Ca 2+ release and ROS regulation. Cell cycle studies indicated that compound 3a 1 induced cell cycle arrest at the G 2 /M phase by inhibition of CDK activity and activation of the p53 protein.
This study suggests that the rational design of 2-chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives under the combination principle is a feasible method to discover new antitumor therapeutics.
Experimental
Materials
All chemicals of reagent grade were commercially available and used without further purication. NMR spectra were assayed on a BRUKER AVANCE AV 400/500 spectrometer using tetramethyl silane (TMS) as the internal standard. Mass spectra were obtained on a BRUKER ESQUIRE HCT spectrometer. The GelRed nucleic acid stain was purchased from Biotium.
General synthesis procedure for compounds 3(3a 1 À3d 6 )
2-Chloro-quinoline-3-carbaldehyde derivatives 2(2aÀ2d) were synthesized by condensation of acetanilide derivatives 1(1aÀ1d) with DMF in the presence of phosphorus oxychloride, according to our previous study. 15 2-Chloro-quinoline 3-carbaldehyde derivatives 2(2aÀ2d) (1 mmol), o-phenylenediamine derivatives (1 mmol) and 3 mL methanol were mixed in a pressure tube and heated at 90 C for 4 h. Aer the reaction, the mixture was cooled to room temperature and ltered to obtain the product as yellow powder. If necessary, the target compounds 3(3a 1 À3d 6 ) were puried by column chromatography (silica 300-400 mesh) with acetic ether-petroleum benzine (v/v: 1/5) as an eluent. 3a 1 . 
Biological assays
The procedures for biological assays are described in the ESI † (Part 1). The materials, instrumentation, and methods for the cytotoxicity assay, cell cycle analysis, cell apoptosis analysis and western blot assays were reported previously.
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